Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity

Abstract Obesity is a prevalent chronic disorder and a well-known risk factor for cardiovascular disease. However, the evidence of treating obesity for primary prevention of major cardiovascular events is still scarce and controversial. In this review, we provided a comprehensive description of the...

Full description

Saved in:
Bibliographic Details
Published in:European journal of preventive cardiology 2023-11, Vol.30 (17), p.1895-1905
Main Authors: Stumpf, Matheo A M, Cercato, Cintia, de Melo, Maria E, Santos, Raul D, Mancini, Marcio C
Format: Article
Language:English
Subjects:
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucagon-Like Peptide 1
Humans
Hypoglycemic Agents
Obesity - complications
Obesity - epidemiology
Primary Prevention
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Obesity is a prevalent chronic disorder and a well-known risk factor for cardiovascular disease. However, the evidence of treating obesity for primary prevention of major cardiovascular events is still scarce and controversial. In this review, we provided a comprehensive description of the current evidence in treating obesity regarding cardiovascular protection. Bariatric surgery appears to be the most robust method to reduce events in people without established cardiovascular disease. High compliance to lifestyle interventions can further reduce cardiovascular risk. Concerning pharmacological therapies, a post hoc analysis from SUSTAIN-6 and a meta-analysis from STEP trials suggest that semaglutide, a GLP-1 receptor agonist, could reduce cardiovascular events in people without established cardiovascular disease. The first study addressed specifically a high-risk population with diabetes and, the second, low- or intermediary-risk individuals without diabetes. Tirzepatide, a novel dual GIP/GLP-1 agonist, although not yet tested in specific cardiovascular outcomes trials, could be an alternative since it induces loss in weight similar to the achieved by bariatric surgery. Therefore, extrapolated data in distinct baseline cardiovascular risk populations suggest that these two drugs could be used in primary prevention with the aim of preventing cardiovascular events, but the grade of this evidence is still low. Specifically designed studies are needed to address this specific topic.
ISSN:2047-4873
2047-4881
DOI:10.1093/eurjpc/zwad280